image
Rigel Pharmaceuticals, Inc. RIGL
Healthcare - Biotechnology - NASDAQ - US
Watchlist
$ 18.93
1.5 %
$ 338 M
Market Cap
9.06
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one RIGL stock under the worst case scenario is HIDDEN Compared to the current market price of 18.9 USD, Rigel Pharmaceuticals, Inc. is HIDDEN

RIGL Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one RIGL stock under the base case scenario is HIDDEN Compared to the current market price of 18.9 USD, Rigel Pharmaceuticals, Inc. is HIDDEN

RIGL Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one RIGL stock under the best case scenario is HIDDEN Compared to the current market price of 18.9 USD, Rigel Pharmaceuticals, Inc. is HIDDEN

RIGL Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart RIGL

image
1M -14.0%
6M 9%
1Y 143%
3Y 37%
5Y -4%
All
$25.0$25.0$24.0$24.0$23.0$23.0$22.0$22.0$21.0$21.0$20.0$20.0$19.0$19.0$18.0$18.0$17.0$17.0$16.0$16.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
179 M REVENUE
53.38%
Growth Rates
1Year 53.38%
3Years 6.30%
5Years 24.77%
7Years 69.37%
10Years 36.05%
24.2 M OPERATING INCOME
218.06%
Growth Rates
1Year 218.06%
3Years 67.45%
5Years 18.64%
7Years 12.66%
10Years 8.52%
17.5 M NET INCOME
169.69%
Growth Rates
1Year 169.69%
3Years 43.84%
5Years 17.73%
7Years 12.10%
10Years 8.17%
31.5 M OPERATING CASH FLOW
647.99%
Growth Rates
1Year 647.99%
3Years 74.94%
5Years 22.50%
7Years 13.36%
10Years 9.38%
4.13 M INVESTING CASH FLOW
196.11%
Growth Rates
1Year 196.11%
3Years 27.07%
5Years 16.81%
7Years 12.01%
10Years -23.84%
-11.6 M FINANCING CASH FLOW
-63.38%
Growth Rates
1Year -63.38%
3Years -5.84%
5Years -15.15%
7Years -1.36%
10Years -27.04%
53.3 M REVENUE
-7.40%
Growth Rates
1Year 53.38%
3Years 6.30%
5Years 24.77%
7Years 69.37%
10Years 36.05%
12.8 M OPERATING INCOME
-23.31%
Growth Rates
1Year 218.06%
3Years 67.45%
5Years 18.64%
7Years 12.66%
10Years 8.52%
11.4 M NET INCOME
-20.19%
Growth Rates
1Year 169.69%
3Years 43.84%
5Years 17.73%
7Years 12.10%
10Years 8.17%
-893 K OPERATING CASH FLOW
-6.16%
Growth Rates
1Year 647.99%
3Years 74.94%
5Years 22.50%
7Years 13.36%
10Years 9.38%
-10.6 M INVESTING CASH FLOW
3.32%
Growth Rates
1Year 196.11%
3Years 27.07%
5Years 16.81%
7Years 12.01%
10Years -23.84%
484 K FINANCING CASH FLOW
-66.96%
Growth Rates
1Year -63.38%
3Years -5.84%
5Years -15.15%
7Years -1.36%
10Years -27.04%
Balance Sheet Rigel Pharmaceuticals, Inc.
image
Current Assets 135 M
Cash & Short-Term Investments 77.3 M
Receivables 41.6 M
Other Current Assets 16.2 M
Non-Current Assets 28.9 M
Long-Term Investments 0
PP&E 338 K
Other Non-Current Assets 28.5 M
47.15 %25.38 %9.86 %17.40 %Total Assets$164.0m
Current Liabilities 63.3 M
Accounts Payable 3.34 M
Short-Term Debt 7.56 M
Other Current Liabilities 52.4 M
Non-Current Liabilities 97.4 M
Long-Term Debt 52.4 M
Other Non-Current Liabilities 45 M
4.70 %32.61 %32.61 %27.99 %Total Liabilities$160.7m
EFFICIENCY
Earnings Waterfall Rigel Pharmaceuticals, Inc.
image
Revenue 179 M
Cost Of Revenue 18.6 M
Gross Profit 161 M
Operating Expenses 136 M
Operating Income 24.2 M
Other Expenses 6.71 M
Net Income 17.5 M
180m180m160m160m140m140m120m120m100m100m80m80m60m60m40m40m20m20m00179m(19m)161m(136m)24m(7m)17mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
89.60% GROSS MARGIN
89.60%
Averages
1Year 89.60%
3Years 94.02%
5Years 96.10%
7Years 96.91%
10Years -58.22%
13.49% OPERATING MARGIN
13.49%
Averages
1Year 13.49%
3Years -16.38%
5Years -16.37%
7Years -51.67%
10Years -265.84%
9.75% NET MARGIN
9.75%
Averages
1Year 9.75%
3Years -20.98%
5Years -20.58%
7Years -53.36%
10Years -263.05%
531.78% ROE
531.78%
Averages
1Year 531.78%
3Years 357.25%
5Years 184.69%
7Years 105.09%
10Years 47.61%
10.66% ROA
10.66%
Averages
1Year 10.66%
3Years -18.87%
5Years -18.97%
7Years -27.23%
10Years -38.37%
21.28% ROIC
21.28%
Averages
1Year 21.28%
3Years -28.97%
5Years -25.71%
7Years -37.43%
10Years -52.33%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Rigel Pharmaceuticals, Inc.
image
40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 17.5 M
Depreciation & Amortization 2.23 M
Capital Expenditures -36 K
Stock-Based Compensation 12.4 M
Change in Working Capital 0
Others -788 K
Free Cash Flow 31.4 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Rigel Pharmaceuticals, Inc.
image
RIGL has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 4
6. Ownership
Insider Ownership Rigel Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
424 K USD 4
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Is Rigel Pharmaceuticals (RIGL) Stock Undervalued Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 1 month ago
Wall Street Analysts See a 71.97% Upside in Rigel (RIGL): Can the Stock Really Move This High? The consensus price target hints at a 72% upside potential for Rigel (RIGL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com - 1 month ago
Rigel to Present at the Jefferies Global Healthcare Conference SOUTH SAN FRANCISCO, Calif. , May 28, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 12:50 p.m. prnewswire.com - 1 month ago
Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress Final data from the GAVRETO® (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive NSCLC and other solid tumors   Supportive data for REZLIDHIA® (olutasidenib) utilization in patients with mIDH1 R/R AML SOUTH SAN FRANCISCO, Calif. , May 22, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced seven upcoming poster presentations at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) 2025 Congress. prnewswire.com - 1 month ago
Here's Why Rigel (RIGL) Is a Great 'Buy the Bottom' Stock Now Rigel (RIGL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. zacks.com - 1 month ago
Is Rigel Pharmaceuticals (RIGL) a Great Value Stock Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 1 month ago
Earnings Estimates Rising for Rigel (RIGL): Will It Gain? Rigel (RIGL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions. zacks.com - 1 month ago
Wall Street Analysts Think Rigel (RIGL) Could Surge 82.3%: Read This Before Placing a Bet The mean of analysts' price targets for Rigel (RIGL) points to an 82.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. zacks.com - 1 month ago
Rigel Pharmaceuticals: Q1 Earnings Showcase Growing Momentum Rigel Pharmaceuticals, Inc. shows strong momentum, with a 68% YoY revenue increase, driven by TAVALISSE, GAVRETO, and REZLIDHIA, suggesting a shift to a durable growth stock. Q1 net income of $11.4M and improved gross margins highlight Rigel's operating leverage, reducing the need for dilutive fundraising and supporting future R&D investments. R289's promising pipeline progress and TAVALISSE's patent extension to 2032 bolster Rigel's long-term outlook, despite reliance on key products and competitive markets. seekingalpha.com - 2 months ago
Rigel Pharmaceuticals, Inc. (RIGL) Q1 2025 Earnings Call Transcript Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Ray Furey - Executive Vice President, General Counsel & Corporate Secretary. Raul Rodriguez - President & Chief Executive Officer Dave Santos - Chief Commercial Officer Lisa Rojkjaer - Chief Medical Officer Dean Schorno - Chief Financial Officer Conference Call Participants Kalpit Patel - B. seekingalpha.com - 2 months ago
Rigel Pharmaceuticals (RIGL) Beats Q1 Earnings and Revenue Estimates Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to loss of $0.50 per share a year ago. zacks.com - 2 months ago
Rigel Reports First Quarter 2025 Financial Results and Provides Business Update First quarter 2025 total revenue of approximately $53.3 million, which includes net product sales of $43.6 million and contract revenues from collaborations of $9.8 million Generated $11.4 million of net income in the first quarter of 2025 R289 granted Orphan Drug designation for the treatment of MDS and Fast Track designation for the treatment of previously-treated transfusion dependent lower-risk MDS by the FDA 2025 Outlook: Total revenue of approximately $200 to $210 million Conference call and webcast scheduled today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif. prnewswire.com - 2 months ago
8. Profile Summary

Rigel Pharmaceuticals, Inc. RIGL

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 338 M
Dividend Yield 0.00%
Description Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Contact 1180 Veterans Boulevard, South San Francisco, CA, 94080 https://www.rigel.com
IPO Date Nov. 29, 2000
Employees 162
Officers Mr. Joseph Lasaga Executive Vice President & Chief Business Officer Mr. Raymond J. Furey J.D. Executive Vice President, Chief Compliance Officer, General Counsel & Corporate Secretary Mr. Tarek Sallam Vice President of Marketing Mr. Dean L. Schorno CPA Executive Vice President & Chief Financial Officer Mr. David A. Santos Executive Vice President & Chief Commercial Officer Mr. Raul R. Rodriguez President, Chief Executive Officer & Director Dr. Lisa Rojkjaer M.D. Executive Vice President & Chief Medical Officer Ms. Julie Patel Senior Vice President of Human Resources